Loss of the Urothelial Differentiation Marker FOXA1 Is Associated with High Grade, Late Stage Bladder Cancer and Increased Tumor ProliferationDavid J. DeGraff, Robert J. Matusik, Peter E. Clark et al.|PLoS ONE|2012Cited by 111
Microdosimetric calculation of relative biological effectiveness for design of therapeutic proton beams Yuki Kase, S. Murayama, W. Yamashita et al.|Journal of Radiation Research|2012Cited by 82
Bone Metastasis of Prostate Cancer Can Be Therapeutically Targeted at the TBX2–WNT Signaling AxisSrinivas Nandana, Leland W.K. Chung, Manisha Tripathi et al.|Cancer Research|2017Cited by 77
Loss of FOXA1 Drives Sexually Dimorphic Changes in Urothelial Differentiation and Is an Independent Predictor of Poor Prognosis in Bladder CancerOpal L. Reddy, David J. DeGraff, Justin Cates et al.|American Journal Of Pathology|2015Cited by 71
Clinical Comparison of Proton Beam Therapy and Stereotactic Body Radiation Therapy for Medically Inoperable Stage I Non-small Cell Lung CancerH. Harada, T. Nishimura, S. Murayama et al.|International Journal of Radiation Oncology*Biology*Physics|2012Cited by 2